The Myriad case has been closely watched by the biotechnology industry, with some insiders suggesting that a ruling against gene patenting could have a devastating effect on future innovation.

The Supreme Court ruled last week in a separate case involving medical diagnostics that companies cannot patent observations about a natural phenomenon. On Monday, it asked the lower court to revisit the Myriad case to view how it may or may not relate to that decision.

The move is expected to delay a verdict in the Myriad case by as much as several years. In the case of the individual company, that may give it enough time to benefit from the use of its contested patents. Shares in Myriad rose over 3 percent.

"Our intellectual property consultant could potentially see a scenario where the case doesn't move its way back to the Supreme Court for another 2 to 3 plus years, keeping the BRACAnalysis franchise safe from competition," said Junaid Husain, a research analyst for Dougherty & Co.

Women who test positive using Myriad's gene test, called BRACAnalysis, have an 82 percent higher risk of developing breast cancer and a 44 percent higher risk of ovarian cancer in their lifetimes. Such tests could help determine a future course of therapy.

The appeals court by a 2-1 vote had ruled the genes isolated by the company could be patented because Myriad is testing for distinctive chemical forms of the genes, and not as they appear naturally in the body. The dissenting judge said the genes could not be patented just because they were isolated from the body.

The patents granted to Myriad give the company the exclusive right to perform the genetic tests. The appeals court in its ruling in July also found that Myriad's method for screening potential therapies can be patented.

The appeals court had overturned a ruling by a federal judge in New York that the genes could not be patented.

HOW BIG A HURDLE?

Michael Yee, biotech analyst for RBC Capital Markets, said the Supreme Court not taking up the case on Monday was positive for the biotechnology industry.

See the original post:
Supreme Court throws out human gene patents

Recommendation and review posted by Bethany Smith

Public release date: 28-Mar-2012 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 x2156 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY -- A novel method for printing human cells onto surfaces in defined patterns can help advance research on tissue engineering and regeneration, as described in an article in Tissue Engineering, Part C, Methods, a peer-reviewed journal from Mary Ann Liebert, Inc (http://www.liebertpub.com). The article is available free online at the Tissue Engineering website (http://www.liebertpub.com/ten).

"Cell printing is one of the breakthrough technologies that will make the application of stem cells for tissue engineering feasible," says John Jansen, DDS, PhD, Methods Co-Editor-in-Chief and Professor and Chairman, Department of Biomaterials, Radboud University Nijmegen Medical Center, The Netherlands.

Yu Fang and colleagues, University of Michigan, Ann Arbor, combined two microscale techniques to dispense and position cells in a variety of patterns. They then demonstrated the ability to use these 3-dimensional cell systems to monitor cell signaling events known to have a role in the growth, proliferation, and metastasis of cancer cells. The authors describe the use of sound waves to deliver microdroplets of cells and polymer-based phase separation to control cell placement in the article "Rapid Generation of Multiplexed Cell Co-Cultures Using Acoustic Droplet Ejection Followed by Aqueous Two-phase Exclusion Patterning." (http://online.liebertpub.com/doi/abs/10.1089/ten.TEC.2011.0709)

###

About the Journal

Tissue Engineering (http://www.liebertpub.com/ten) is an authoritative peer-reviewed journal published monthly in print and online in three parts: Part A--the flagship journal; Part BReviews; and Part CMethods. Led by Co-Editors-In-Chief Antonios Mikos, PhD, Louis Calder Professor at Rice University, Houston, TX, and Peter C. Johnson, MD, Vice President, Research and Development, Avery Dennison Medical Solutions of Chicago, IL and President and CEO, Scintellix, LLC, Raleigh, NC, the Journal brings together scientific and medical experts in the fields of biomedical engineering, material science, molecular and cellular biology, and genetic engineering. Tissue Engineering is the official journal of the Tissue Engineering & Regenerative Medicine International Society (TERMIS). Complete tables of content and a sample issue may be viewed online at the Tissue Engineering website (http://www.liebertpub.com/ten).

About the Company

Mary Ann Liebert, Inc.(http://www.liebertpub.com), is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Stem Cells and Development, Human Gene Therapy and HGT Methods, and Biopreservation and Biobanking. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available at Mary Ann Liebert Inc. (http://www.liebertpub.com).

The rest is here:
Innovative cell printing technologies hold promise for tissue engineering R&D

Recommendation and review posted by Bethany Smith

Public release date: 28-Mar-2012 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY -- Online romance scams, a new form of cybercrime, is under-reported and increasing, and has victimized an estimated 230,000 people in England, costing them nearly $60 billion a year, according to an article in Cyberpsychology, Behavior, and Social Networking, a peer-reviewed journal published by Mary Ann Liebert, Inc. The article is available free online at the Cyberpsychology, Behavior, and Social Networking website at http://www.liebertpub.com/cyber.

"This crime is very serious and unfortunately often overlooked. The costs to the victim are both hidden (emotional) and more visible (monetary)," says Brenda K. Wiederhold, PhD, MBA, BCIA, Editor-in-Chief of Cyberpsychology, Behavior and Social Networking, from the Interactive Media Institute, San Diego, CA.

Online dating scammers pretend to initiate a romantic relationship through online dating services and then defraud their victims of large sums of money over a period of months or longer. Monica Whitty, University of Leicester, UK, and Tom Buchanan, University of Westminster, London, UK, document the rapid growth in these serious crimes and how cybercriminals pursue and steal from their victims. They describe the devastating financial and emotional losses the victims suffer.

###

About the Journal

Cyberpsychology, Behavior, and Social Networking is an authoritative peer-reviewed journal published monthly in print and online that explores the psychological and social issues surrounding the Internet and interactive technologies. Complete tables of content and a sample issue may be viewed online at the Cyberpsychology, Behavior, and Social Networking website at http://www.liebertpub.com/cyber.

About the Company

Mary Ann Liebert, Inc. is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Games for Health Journal, Telemedicine and e-Health, and Journal of Child and Adolescent Psychopharmacology. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc. website at http://www.liebertpub.com.

Continued here:
Online dating scammers looking for money, not love

Recommendation and review posted by Bethany Smith

By measuring the rate of protein production in bacteria, the team discovered that slight genetic alterations could have a dramatic effect. This was true even for seemingly insignificant genetic changes known as "silent mutations," which swap out a single DNA letter without changing the ultimate gene product. To their surprise, the scientists found these changes can slow the protein production process to one-tenth of its normal speed or less.

As described today in the journal Nature, the speed change is caused by information contained in what are known as redundant codons small pieces of DNA that form part of the genetic code. They were called "redundant" because they were previously thought to contain duplicative rather than unique instructions.

This new discovery challenges half a century of fundamental assumptions in biology. It may also help speed up the industrial production of proteins, which is crucial for making biofuels and biological drugs used to treat many common diseases, ranging from diabetes to cancer.

"The genetic code has been thought to be redundant, but redundant codons are clearly not identical," said Jonathan Weissman, PhD, a Howard Hughes Medical Institute Investigator in the UCSF School of Medicine Department of Cellular andMolecular Pharmacology.

"We didn't understand much about the rules," he added, but the new work suggests nature selects among redundant codons based on genetic speed as well as genetic meaning.

Similarly, a person texting a message to a friend might opt to type, "NP" instead of "No problem." They both mean the same thing, but one is faster to thumb than the other.

How Ribosome Profiling Works

The work addresses an observation scientists have long made that the process protein synthesis, so essential to all living organisms on Earth, is not smooth and uniform, but rather proceeds in fits and starts. Some unknown mechanism seemed to control the speed with which proteins are made, but nobody knew what it was.

To find out, Weissman and UCSF postdoctoral researcher Gene-Wei Li, PhD, drew upon a broader past effort by Weissman and his colleagues to develop a novel laboratory technique called "ribosome profiling," which allows scientists to examine universally which genes are active in a cell and how fast they are being translated into proteins.

Ribosome profiling takes account of gene activity by pilfering from a cell all the molecular machines known as ribosomes. Typical bacterial cells are filled with hundreds of thousands of these ribosomes, and human cells have even more. They play a key role in life by translating genetic messages into proteins. Isolating them and pulling out all their genetic material allows scientists to see what proteins a cell is making and where they are in the process.

See the article here:
Researchers discover new layer of genetic information that helps determine how fast proteins are produced

Recommendation and review posted by Bethany Smith

Public release date: 28-Mar-2012 [ | E-mail | Share ]

Contact: Raymond MacDougall macdougallr@mail.nih.gov 301-402-0911 NIH/National Human Genome Research Institute

Farmers in the highlands of southern Ethiopia scratch out a subsistence living from the region's volcanic red clay. The soil supports the farms, but fine-grained, volcanic rock particles in the dirt threaten the farmers and their families. Continual exposure of bare feet to the volcanic soil causes 1 in 20 people to develop a painful inflammation of the lower extremities that, over time, leads to foot disfigurement. Doctors call it podoconiosis. The locals call it mossy foot. And those affected suffer social stigma as well as debilitating discomfort.

Now, researchers think they know why some 4 million people in at least 10 countries worldwide develop this incapacitating condition. One-fifth carry genetic variants that cause their immune system to react to the volcanic dust. This disease-producing response, triggered by exposure from the lack of shoes, provides a dramatic example of the interaction between genes and the environment.

Writing in the March 29, 2012 New England Journal of Medicine, an international team that includes researchers from the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health, describes the genetic link that turns dirt into a toxin.

"This study draws attention to a neglected tropical disease with a devastating impact on poor people and their communities," said NHGRI Scientific Director Dan Kastner, M.D., Ph.D. "It demonstrates the global reach of genomics research into the lives of people in parts of the world where endemic diseases very often go unchecked."

Doctors have known for a long time that podoconiosis runs in families and that continual exposure to volcanic soil triggers it. Wearing shoes and socks, or even washing off the dirt, prevents the condition. But doctors have been perplexed that only some people develop the disease, while others with the same environmental exposure are spared.

To sort this out, the international collaborators conducted a genome-wide association studyor GWASanalyzing DNA from 194 volunteers from the Ethiopian highlands affected by podoconiosis, along with DNA from another 203 unaffected individuals from the same region. The researchers collaborated with field workers from the non-profit Mossy Foot Treatment and Prevention Association in southern Ethiopia to collect the data and samples.

The researchers generated a dataset from study-participant DNA, screening more than 550,000 single-nucleotide polymorphisms (SNPs), which are sites in an individual's DNA that contain a different chemical base when compared to a standard reference human genome sequence. They found significant podoconiosis association for eight SNPs within or nearby a stretch of DNA on chromosome 6, called the HLA class II locus.

The researchers performed a second validation step, called a family-based association study, using DNA samples from 202 sets of child-parent trios from affected families. The researchers detected six SNPs that showed significant associationthose that mapped to HLA class II region genes and most strongly associated with podoconiosis in the GWAS, validating the GWAS results.

Read more:
Researchers identify genetic basis of tropical foot and leg lymphedema

Recommendation and review posted by Bethany Smith

Newswise A hidden and never before recognized layer of information in the genetic code has been uncovered by a team of scientists at the University of California, San Francisco (UCSF) thanks to a technique developed at UCSF called ribosome profiling, which enables the measurement of gene activity inside living cells including the speed with which proteins are made.

By measuring the rate of protein production in bacteria, the team discovered that slight genetic alterations could have a dramatic effect. This was true even for seemingly insignificant genetic changes known as silent mutations, which swap out a single DNA letter without changing the ultimate gene product. To their surprise, the scientists found these changes can slow the protein production process to one-tenth of its normal speed or less.

As described today in the journal Nature, the speed change is caused by information contained in what are known as redundant codons small pieces of DNA that form part of the genetic code. They were called redundant because they were previously thought to contain duplicative rather than unique instructions.

This new discovery challenges half a century of fundamental assumptions in biology. It may also help speed up the industrial production of proteins, which is crucial for making biofuels and biological drugs used to treat many common diseases, ranging from diabetes to cancer.

The genetic code has been thought to be redundant, but redundant codons are clearly not identical, said Jonathan Weissman, PhD, a Howard Hughes Medical Institute Investigator in the UCSF School of Medicine Department of Cellular and Molecular Pharmacology.

We didn't understand much about the rules, he added, but the new work suggests nature selects among redundant codons based on genetic speed as well as genetic meaning.

Similarly, a person texting a message to a friend might opt to type, NP instead of No problem. They both mean the same thing, but one is faster to thumb than the other. How Ribosome Profiling Works

The work addresses an observation scientists have long made that the process protein synthesis, so essential to all living organisms on Earth, is not smooth and uniform, but rather proceeds in fits and starts. Some unknown mechanism seemed to control the speed with which proteins are made, but nobody knew what it was. Ribosome structure

The structure of a ribosome

To find out, Weissman and UCSF postdoctoral researcher Gene-Wei Li, PhD, drew upon a broader past effort by Weissman and his colleagues to develop a novel laboratory technique called ribosome profiling, which allows scientists to examine universally which genes are active in a cell and how fast they are being translated into proteins.

Original post:
New Layer of Genetic Information Discovered

Recommendation and review posted by Bethany Smith

ScienceDaily (Mar. 28, 2012) A hidden and never before recognized layer of information in the genetic code has been uncovered by a team of scientists at the University of California, San Francisco (UCSF) thanks to a technique developed at UCSF called ribosome profiling, which enables the measurement of gene activity inside living cells -- including the speed with which proteins are made.

By measuring the rate of protein production in bacteria, the team discovered that slight genetic alterations could have a dramatic effect. This was true even for seemingly insignificant genetic changes known as "silent mutations," which swap out a single DNA letter without changing the ultimate gene product. To their surprise, the scientists found these changes can slow the protein production process to one-tenth of its normal speed or less.

As described March 28 in the journal Nature, the speed change is caused by information contained in what are known as redundant codons -- small pieces of DNA that form part of the genetic code. They were called "redundant" because they were previously thought to contain duplicative rather than unique instructions.

This new discovery challenges half a century of fundamental assumptions in biology. It may also help speed up the industrial production of proteins, which is crucial for making biofuels and biological drugs used to treat many common diseases, ranging from diabetes to cancer.

"The genetic code has been thought to be redundant, but redundant codons are clearly not identical," said Jonathan Weissman, PhD, a Howard Hughes Medical Institute Investigator in the UCSF School of Medicine Department of Cellular and Molecular Pharmacology.

"We didn't understand much about the rules," he added, but the new work suggests nature selects among redundant codons based on genetic speed as well as genetic meaning.

Similarly, a person texting a message to a friend might opt to type, "NP" instead of "No problem." They both mean the same thing, but one is faster to thumb than the other.

How Ribosome Profiling Works

The work addresses an observation scientists have long made that the process protein synthesis, so essential to all living organisms on Earth, is not smooth and uniform, but rather proceeds in fits and starts. Some unknown mechanism seemed to control the speed with which proteins are made, but nobody knew what it was.

To find out, Weissman and UCSF postdoctoral researcher Gene-Wei Li, PhD, drew upon a broader past effort by Weissman and his colleagues to develop a novel laboratory technique called "ribosome profiling," which allows scientists to examine universally which genes are active in a cell and how fast they are being translated into proteins.

See original here:
New layer of genetic information helps determine how fast proteins are produced

Recommendation and review posted by Bethany Smith

NEW YORK, NY--(Marketwire -03/28/12)- Biotechnology stocks have been on an impressive run this year as favorable legislation out of Washington is allowing biotech companies of all sizes to more easily navigate regulations. Five Star Equities examines the outlook for companies in the Biotechnology industry and provides equity research on Advanced Cell Technology Inc. (OTC.BB: ACTC.OB - News) and PharmAthene Inc. (AMEX: PIP - News). Access to the full company reports can be found at:

http://www.fivestarequities.com/ACTC http://www.fivestarequities.com/PIP

The Biotechnology Industry Organization (BIO) recently applauded the House Energy and Commerce Committee's passage of the Medicare Decisions Accountability Act, H.R. 452, which would repeal the Independent Payment Advisory Board (IPAB) established in the health care reform law. BIO also issued a press release applauding the Senate on the passage of H.R. 3606, the Jumpstart Our Business Startups (JOBS) Act. The JOBS Act creates an "on-ramp" to the public market for emerging growth companies, allowing them five years to focus on conducting critical research that can lead to cures for debilitating diseases before having to divert funds to costly regulations, BIO reports.

Five Star Equities releases regular market updates on the biotechnology industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.fivestarequities.com and get exclusive access to our numerous stock reports and industry newsletters.

Advanced Cell Technology, Inc., a biotechnology company, focuses on the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine. Earlier this month the company filed with the Securities and Exchange Commission a proxy statement containing a shareholder proposal for a reverse split of its common stock. "This reverse stock split, which should better align the company's capital structure with its stage of development, and an accompanying Nasdaq listing application, will represent a significant step toward creating long-term shareholder value and building ACT into a world-class player in the regenerative medicine space," said Gary Rabin, chairman and CEO of ACT.

PharmAthene, Inc., a biodefense company, engages in the development and commercialization of medical countermeasures against biological and chemical weapons in the United States. For the year ended December 31, 2011, PharmAthene recognized revenue of $24.3 million, compared to $21.0 million in 2010.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.fivestarequities.com/disclaimer

See the original post here:
Advanced Cell Technology and PharmAthene Poised to Benefit From Positive Legislation

Recommendation and review posted by simmons

28-03-2012 10:17 Dr Joshua Hare is Professor of Medicine and Director of the Interdisciplinary Stem Cell Institute at the University of Miami. The interview was conducted on 25 March 2012 at the American College of Cardiology's (ACC's) 61st Annual Scientific Session & Expo in Chicago. See more ACC.12 Coverage: http://www.getinsidehealth.com

Read the original post:
Stem cell therapy for the repair of myocardium in heart failure patients - Video

Recommendation and review posted by simmons

Arkansas State University-Newport will host a Bone Marrow Donor Drive on campus Thursday, March 29 from 10am until 7pm and Saturday, March 31 from 9am until 1pm in the Student/Community Center, Merchants & Planters Insurance and Investments room. A bone marrow transplant is a lifesaving treatment for people with leukemia, lymphoma and many other diseases. First, patients undergo chemotherapy and sometimes radiation to destroy their diseased marrow. Then a donor's healthy blood-forming stem cells are transfused directly into the patient's bloodstream, where they can begin to function and multiply. For a patient's body to accept these healthy cells, the patient needs a donor who is a close match. Seventy percent of patients cannot find a matching donor within their family and depend on the national registry to find an unrelated bone marrow donor. Even with a registry of millions, 6 out of 10 patients NEVER receive the lifesaving transplant they need. Donors of all ethnicities are needed to change this. To see if you can be a bone marrow donor and to read about the process of testing and donating, go to http://www.dkmsamericas.org and click on Get Educated.

Read this article:
ASUN to host Bone Marrow Donor Drive

Recommendation and review posted by Bethany Smith

Volunteers will stake out locations all over Athens today from the downtown Waffle House at 2 a.m., to Athens City Hall at 4 p.m. to encourage people across the city to register for a bone marrow donor list in the hopes of finding a match for two sick locals.

The need is even more urgent because former Clarke County school nurse Thomasene Smith and Athens Academy sixth-grader Kajal Patel are minorities, said Caitlin Martin, a representative of Be The Match, the national bone marrow donor registry program. Be The Match, the University of Georgia, the Omni Club and Athens Academy have joined together to host a marathon, continuing today at locations across Athens, to help find donors for Smith and Patel by signing more people to the donor registry list.

Minorities have such a poor chance of finding a match because more than 90 percent of the people signed up for the registry are white, Martin said.

Race matters when trying to find a match for a bone marrow donation, and often, family members arent the best fit, Martin said.

Only 30 percent of our patrons have matches within their family, she said.

Holding the marathon for Smith and Patel will help people of minority groups learn that sick people need them to register for the bone marrow donor list, said Kelin Johnson, Omni Ambassador and former Georgia defense back.

Once people know that race matters when finding a bone marrow donor, more donors likely will come forward, Johnson said.

I think it just comes from a lack of education or awareness, he said.

Potential donors might also shy away from registering because they think the process will hurt too much, Martin said.

One of the biggest myths is that its painful, and thats not true, she said.

View original post here:
Volunteers work 'round the clock to find bone marrow donors

Recommendation and review posted by Bethany Smith

Displaying rare unanimity on an issue, the full U.S. 9th Circuit Court of Appeals on Tuesday rejected a request by the federal government thatit reconsidera rulingthat most bone marrow donors can be compensated for providing life-saving marrow stem cells from their blood.

A three-judge panel of the appeals court ruled on Dec. 1 that the process of harvesting marrow cells by filtering a donor's blood wasn't covered by the 1984 National Organ Transplant Act's prohibitionof payment for organs or organ parts.The statute was enacted by Congress before the blood-filtering process was developed and donors were subjected to painful and medically risky surgical extraction of marrow by insertion of a siphoning needle into the hip bone. Compensation for that form of donation remains illegal.

Atty. Gen. Eric H. Holder Jr., on behalf of the federal government, petitioned the court in Januaryfor a new hearing by an 11-judge panel. Department of Justice lawyers argued that the December ruling ignored the clear intent of Congress to prevent money from influencing donation decisions.

The 9th Circuit panel said in its latest ruling thatall 25 active judges on the court were informed of the government's request and none called for a vote on it, signaling their agreement with the December decision. That unusualaccord among the judges who span a broad ideological spectrum might also indicate that the U.S. Supreme Court will be unlikely to take the case for review.

The lawsuit challenging the ban on bone marrow compensation was brought by a group of cancer patients and their families, as well as a marrow transplant specialist and a California nonprofit organization, MoreMarrowDonors.org, aiming to expand the registry of available donors by offering up to $3,000 in housing assistance or scholarships for promising genetic matches.

Violation of the organ transplant act's prohibition on sales of organs or parts thereofcarries heavy fines and up to five years in prison.The 1984 act defined bone marrow as an organ part, while the 9th Circuit's ruling said it was a blood part and not subject to theban on compensation.

ALSO:

Mega Millions lottery jackpot soars to $363 million

Trayvon Martin: L.A. rallies voice outrage at shooting

First defendants graduate from L.A. County Veterans Court

Read the original:
Appeals court stands united on compensation for bone marrow donors

Recommendation and review posted by Bethany Smith

ScienceDaily (Mar. 26, 2012) A breakthrough using cutting-edge stem cell research could speed up the discovery of new treatments for motor neuron disease (MND).

The international research team has created motor neurons using skin cells from a patient with an inherited form of MND.

Role of protein

Using patient stem cells to model MND in a dish offers untold possibilities for how we study the cause of this terrible disease as well as accelerating drug discovery by providing a cost-effective way to test many thousands of potential treatments said Professor Siddharthan Chandran, Director of the University's Euan MacDonald Centre for MND Research.

The study discovered that abnormalities of a protein called TDP-43, implicated in more than 90 per cent of cases of MND, resulted in the death of motor neuron cells.

This is the first time that scientists have been able to see the direct effect of abnormal TDP-43 on human motor neurons.

The study, led by the University of Edinburgh's Euan MacDonald Centre for Motor Neuron Disease Research, was carried out in partnership with King's College London, Columbia University, New York and the University of San Francisco.

Motor neuron disease

MND is a devastating, untreatable and ultimately fatal condition that results from progressive loss of the motor nerves -- motor neurons -- that control movement, speech and breathing.

The study, funded by the MND Association, is published in the journal Proceedings of the National Academy of Sciences.

View post:
Stem cell study aids quest for motor neuron disease therapies

Recommendation and review posted by Bethany Smith

MADISON, Wis., March 28, 2012 /PRNewswire/ --Cellular Dynamics International, Inc. (CDI) today announced an expansion of its existing distribution agreement with iPS Academia Japan, Inc. to include iCell Neurons and iCell Endothelial Cells. The original distribution agreement, announced on June 8, 2011, covered the distribution of CDI's iCell Cardiomyocytes, the first commercially available product based on induced pluripotent stem cells (iPSCs), in Japan.

CDI is the world's largest manufacturer of human cellular tools for drug discovery and safety derived from iPSCs. The company currently manufactures iCell Cardiomyocytes, iCell Neurons and iCell Endothelial Cells with several other cell types, including liver cells, in development.

iPS Academia Japan was originally established to manage the patents and technology arising from the work of Shinya Yamanaka, MD, PhD of Kyoto University. CDI was the first foreign company granted a license to Yamanaka's iPSC patent portfolio by iPS Academia Japan, announced in May 2010.

"The reliability and consistent quality of CDI's cardiomyocytes have proven to be a valuable product offering to our academic and pharmaceutical customers," said Shosaku Murayama, President and CEO of iPS Academia Japan. "We're already seeing demand for additional human cell types manufactured by CDI by our Japanese customers."

Robert Palay, CEO and chairman of the board of CDI, noted, "We view the expansion of our distribution agreement with iPS Academia Japan as a vote of confidence in our ability to provide human iPSC-derived cells in the quantity, quality and purity required for scientists to realize the full potential of their experiments. We look forward to future growth of our relationship with iPS Academia Japan as we launch new human cell types and in vitro human disease models."

About Cellular Dynamics International Cellular Dynamics International, Inc. (CDI) is a leading developer of next-generation stem cell technologies for drug development, cell therapy, tissue engineering and organ regeneration. CDI harnesses its unique manufacturing technology to produce differentiated tissue cells from any individual's stem cell line in industrial quality, quantity and purity. CDI is accelerating the adoption of pluripotent stem cell technology, adapting its methods to fit into standard clinical practice by the creation of individual stem cell lines from a standard blood draw. CDI was founded in 2004 by Dr. James Thomson, a pioneer in human pluripotent stem cell research at the University of Wisconsin-Madison. CDI's facilities are located in Madison, Wisconsin. See http://www.cellulardynamics.com.

About iPS Academia Japan, Inc. iPS Academia Japan, Inc. (AJ) is an affiliate of Kyoto University, and its main role is, among other activities, to manage and utilize the patents and other intellectual properties held/controlled by Kyoto University and other universities in the field of iPSC technologies so that the research results contribute to health and welfare worldwide.

AJ was established in Kyoto in June 2008. AJ's patent portfolio consists of about 60 patent families (the total number of patent applications is about 220 cases) in the iPSC technology as of March 2012, and about 50 license arrangements have been executed with domestic or international enterprises. See http://ips-cell.net.

Here is the original post:
Cellular Dynamics Expands Distribution Agreement with iPS Academia Japan, Inc. to Include Distribution of iCell ...

Recommendation and review posted by Bethany Smith

TAMPA, Fla.--(BUSINESS WIRE)--

Innovaro, Inc (NYSE Amex: INV), The Innovation Solutions Company, is pleased to announce that its client Inven2, the technology transfer office at Oslo University Hospital and University of Oslo, has entered into an exclusive licensing agreement with Oxford Gene Technology (OGT) for 12 highly promising colorectal cancer tissue biomarkers through Innovaros Pharmalicensing Partnering Search & Profiling division.

The exclusive license allows OGT to commercialize any resulting test developed using these biomarkers and to sublicense the markers to other parties. The DNA methylation biomarkers were developed in the laboratory of Professor Ragnhild A. Lothe, in the department of Cancer Prevention, the Norwegian Radium Hospital, part of the Oslo University Hospital.

OGT has validated the results obtained in Professor Lothes laboratory showing sensitivity of 93% and specificity of 90% when using tissue biopsies. Further work investigating the efficacy of these biomarkers in blood and fecal samples is ongoing.

We fully support the collaboration with Oxford Gene Technology to develop a new method of detecting colorectal cancer using these biomarkers. This agreement demonstrates the importance of industry and academic collaboration in turning scientific excellence into products that address medical needs, commented Benedicte Bakke, Business Development Manager at Inven2. The Innovaro Pharmalicensing Profiling service was able to bring this high quality potential partner to our attention that we may not otherwise have met.

This licensing agreement gives OGT exclusive access to genetic markers which are associated with colorectal cancer, stated Mike Evans, CEO of OGT. We believe that developing tests that include these genetic markers will permit the earlier identification of patients at risk of this disease and allow for more timely diagnosis and clinical interventions. He added, The higher specificity of this new panel of markers could prove a more robust screening tool than the tests currently used, while eventually lowering overall costs, which would be of significant benefit for both patients and the clinicians using them.

We are delighted that Inven2 was able to identify Oxford Gene Technology as an appropriate candidate partner, using Innovaro Pharmalicensings Profiling service, clearly leading to this important licensing agreement, confirmed Mark McBride, Senior VP Fulfilment Services, Innovaro, Inc. This agreement also demonstrates the effectiveness of Innovaros Pharmalicensing Profiling service for the life sciences alongside our already well recognized proficiency in Partnering Search services.

About Inven2

Inven2 is the Technology Transfer Office for the University of Oslo and Oslo University Hospital, Norway's largest and leading university and hospital representing pioneering research. Inven2 is the largest contributor in Norway within the field of commercialization of research across Life Sciences. For more information on Inven2, please visit its website at http://www.inven2.com.

About Oxford Gene Technology

Read more from the original source:
Innovaro Announces Completion of Licensing Agreement between Inven2 and Oxford Gene Technology

Recommendation and review posted by Bethany Smith

AMSTERDAM, The Netherlands, March 28, 2012 /PRNewswire/ --

Amsterdam Molecular Therapeutics (Euronext: AMT - News), a leader in the field of human gene therapy, announced today data demonstrating that one-time administration of the gene therapy Glybera (alipogene tiparvovec) is able to markedly improve chylomicron (fat particles in the blood) metabolism following consumption of a low fat meal. This results in a much reduced level of newly-formed chylomicrons in the bloodstream, which are considered to be the cause of the acute and recurring bouts of pancreatitis seen in lipoprotein lipase deficiency (LPLD) subjects. LPLD is a very rare inherited condition that is associated with increased levels of chylomicrons. These particles carry certain types of fat in the blood, which because they are not removed from the body can cause recurrent pancreatitis. Data were published online in the Journal of Clinical Endocrinology & Metabolism (JCEM, Mar 2012).

"These data show that Glybera has a profound impact on chylomicron metabolism 14 weeks after a single administration. Although the patient cohort is small, due to the rare nature of LPLD, these results are very encouraging," explained Dr. Andr Carpentier, Division of Endocrinology at the Universit de Sherbrooke, Quebec, Candada. "LPLD patients often suffer from extremely painful bouts of pancreatitis, which is believed to be caused by the accumulation of chylomicron particles in the blood."

"This publication provides additional, independent support on the ability of Glybera to restore chylomicron metabolism in LPLD patients. We believe by restoring the body's ability to metabolize these particles in LPLD patients, Glybera treatment results in fewer pancreatitis attacks," stated Carlos Camozzi, Chief Medical Officer at AMT. "LPLD patients are under constant risk of these attacks and the associated excruciating pain."

Study Details

In an open label clinical trial (CT-AMT-011-02), 5 LPLD subjects in Quebec, Canada, were administered alipogene tiparvovec at a dose of 1 x 1012 genome copies per kg. Two weeks before and 14 weeks after administration, chylomicron metabolism, and plasma palmitate (fatty acid) and glycerol appearance rates were determined following ingestion of a low fat meal. Following administration of alipogene tiparvovec, the triglyceride (TG) content of the chylomicron fraction and the chylomicron-triglyceride (TG)/total plasma TG ratio were reduced throughout the postprandial period. The postprandial peak chylomicron level and chylomicron AUC were greatly reduced (by 79% and 93%, 6- and 24 hours after the test meal, respectively). There were no significant changes in plasma fatty acid and glycerol appearance rates. Plasma glucose, insulin and C-peptide also did not change. The data was obtained from AMT's study in patients treated with Glybera in 2009.

About Glybera

AMT has developed Glybera as a treatment for patients with the genetic disorder lipoprotein lipase deficiency.

LPLD is an orphan disease for which no treatment exists today. The disease is caused by mutations in the LPL gene, resulting in highly decreased or absent activity of LPL protein in patients. This protein is needed in order to break down large fat-carrying particles that circulate in the blood after each meal. When such particles, called chylomicrons, accumulate in the blood, they may obstruct small blood vessels. Excess chylomicrons result in recurrent and severe acute inflammation of the pancreas, called pancreatitis, the most debilitating and life threatening clinical complication of LPLD. Glybera has orphan drug status in the EU and US.

About Amsterdam Molecular Therapeutics

Read the original post:
Amsterdam Molecular Therapeutics Publishes Positive Data from Glybera® 14 Week Study

Recommendation and review posted by Bethany Smith

ScienceDaily (Mar. 27, 2012) A team of researchers led by scientists at Weill Cornell Medical College has designed what appears to be a powerful gene therapy strategy that can treat both beta-thalassemia disease and sickle cell anemia. They have also developed a test to predict patient response before treatment.

This study's findings, published in PLoS ONE, represents a new approach to treating these related, and serious, red blood cells disorders, say the investigators.

"This gene therapy technique has the potential to cure many patients, especially if we prescreen them to predict their response using just a few of their cells in a test tube," says the study's lead investigator, Dr. Stefano Rivella, Ph.D., an associate professor of genetic medicine at Weill Cornell Medical College. He led a team of 17 researchers in three countries.

Dr. Rivella says this is the first time investigators have been able to correlate the outcome of transferring a healthy beta-globin gene into diseased cells with increased production of normal hemoglobin -- which has long been a barrier to effective treatment of these disease.

So far, only one patient in France has been treated with gene therapy for beta thalassemia, and Dr. Rivella and his colleagues believe the new treatment they developed will be a significant improvement. No known patient has received gene therapy yet to treat sickle cell anemia.

A Fresh Approach to Gene Therapy

Beta-thalassemia is an inherited disease caused by defects in the beta-globin gene. This gene produces an essential part of the hemoglobin protein, which, in the form of red blood cells, carries life-sustaining oxygen throughout the body.

The new gene transfer technique developed by Dr. Rivella and his colleagues ensures that the beta-globin gene that is delivered will be active, and that it will also provide more curative beta-globin protein. "Since the defect in thalassemia is lack of production of beta-globin protein in red blood cells, this is very important," Dr. Rivella says.

The researchers achieved this advance by hooking an "ankyrin insulator" to the beta-globin gene that is carried by a lentivirus vector. During the gene transfer, this vector would be inserted into bone marrow stem cells taken from patients, and then delivered back via a bone marrow transplant. The stem cells would then produce healthy beta-globin protein and hemoglobin.

This ankyrin insulator achieves two goals. First, it protects delivery of the normal beta-globin gene. "In many gene therapy applications, a curative gene is introduced into the cells of patients in an indiscriminate fashion," Dr. Rivella explains. "The gene lands randomly in the genome of the patient, but where it lands is very important because not all regions of the genome are the same." For example, some therapeutic genes may land in an area of the genome that is normally silenced -- meaning the genes in this area are not expressed. "The role of ankyrin insulator is to create an active area in the genome where the new gene can work efficiently no matter where it lands," Dr. Rivella says. He adds that the small insulator used in his vector should eliminate the kind of side effects seen in the French patient treated with beta-thalassemia gene therapy.

Follow this link:
New gene therapy approach developed for red blood cell disorders

Recommendation and review posted by Bethany Smith

Volunteers will stake out locations all over Athens today from the downtown Waffle House at 2 a.m., to Athens City Hall at 4 p.m. to encourage people across the city to register for a bone marrow donor list in the hopes of finding a match for two sick locals.

The need is even more urgent because former Clarke County school nurse Thomasene Smith and Athens Academy sixth-grader Kajal Patel are minorities, said Caitlin Martin, a representative of Be The Match, the national bone marrow donor registry program. Be The Match, the University of Georgia, the Omni Club and Athens Academy have joined together to host a marathon, continuing today at locations across Athens, to help find donors for Smith and Patel by signing more people to the donor registry list.

Minorities have such a poor chance of finding a match because more than 90 percent of the people signed up for the registry are white, Martin said.

Race matters when trying to find a match for a bone marrow donation, and often, family members arent the best fit, Martin said.

Only 30 percent of our patrons have matches within their family, she said.

Holding the marathon for Smith and Patel will help people of minority groups learn that sick people need them to register for the bone marrow donor list, said Kelin Johnson, Omni Ambassador and former Georgia defense back.

Once people know that race matters when finding a bone marrow donor, more donors likely will come forward, Johnson said.

I think it just comes from a lack of education or awareness, he said.

Potential donors might also shy away from registering because they think the process will hurt too much, Martin said.

One of the biggest myths is that its painful, and thats not true, she said.

See the original post here:
Volunteers work 'round the clock to find bone marrow donors

Recommendation and review posted by sam

Displaying rare unanimity on an issue, the full U.S. 9th Circuit Court of Appeals on Tuesday rejected a request by the federal government thatit reconsidera rulingthat most bone marrow donors can be compensated for providing life-saving marrow stem cells from their blood.

A three-judge panel of the appeals court ruled on Dec. 1 that the process of harvesting marrow cells by filtering a donor's blood wasn't covered by the 1984 National Organ Transplant Act's prohibitionof payment for organs or organ parts.The statute was enacted by Congress before the blood-filtering process was developed and donors were subjected to painful and medically risky surgical extraction of marrow by insertion of a siphoning needle into the hip bone. Compensation for that form of donation remains illegal.

Atty. Gen. Eric H. Holder Jr., on behalf of the federal government, petitioned the court in Januaryfor a new hearing by an 11-judge panel. Department of Justice lawyers argued that the December ruling ignored the clear intent of Congress to prevent money from influencing donation decisions.

The 9th Circuit panel said in its latest ruling thatall 25 active judges on the court were informed of the government's request and none called for a vote on it, signaling their agreement with the December decision. That unusualaccord among the judges who span a broad ideological spectrum might also indicate that the U.S. Supreme Court will be unlikely to take the case for review.

The lawsuit challenging the ban on bone marrow compensation was brought by a group of cancer patients and their families, as well as a marrow transplant specialist and a California nonprofit organization, MoreMarrowDonors.org, aiming to expand the registry of available donors by offering up to $3,000 in housing assistance or scholarships for promising genetic matches.

Violation of the organ transplant act's prohibition on sales of organs or parts thereofcarries heavy fines and up to five years in prison.The 1984 act defined bone marrow as an organ part, while the 9th Circuit's ruling said it was a blood part and not subject to theban on compensation.

ALSO:

Mega Millions lottery jackpot soars to $363 million

Trayvon Martin: L.A. rallies voice outrage at shooting

First defendants graduate from L.A. County Veterans Court

Continue reading here:
Appeals court stands united on compensation for bone marrow donors

Recommendation and review posted by sam

ScienceDaily (Mar. 26, 2012) A breakthrough using cutting-edge stem cell research could speed up the discovery of new treatments for motor neuron disease (MND).

The international research team has created motor neurons using skin cells from a patient with an inherited form of MND.

Role of protein

Using patient stem cells to model MND in a dish offers untold possibilities for how we study the cause of this terrible disease as well as accelerating drug discovery by providing a cost-effective way to test many thousands of potential treatments said Professor Siddharthan Chandran, Director of the University's Euan MacDonald Centre for MND Research.

The study discovered that abnormalities of a protein called TDP-43, implicated in more than 90 per cent of cases of MND, resulted in the death of motor neuron cells.

This is the first time that scientists have been able to see the direct effect of abnormal TDP-43 on human motor neurons.

The study, led by the University of Edinburgh's Euan MacDonald Centre for Motor Neuron Disease Research, was carried out in partnership with King's College London, Columbia University, New York and the University of San Francisco.

Motor neuron disease

MND is a devastating, untreatable and ultimately fatal condition that results from progressive loss of the motor nerves -- motor neurons -- that control movement, speech and breathing.

The study, funded by the MND Association, is published in the journal Proceedings of the National Academy of Sciences.

Here is the original post:
Stem cell study aids quest for motor neuron disease therapies

Recommendation and review posted by sam

MADISON, Wis., March 28, 2012 /PRNewswire/ --Cellular Dynamics International, Inc. (CDI) today announced an expansion of its existing distribution agreement with iPS Academia Japan, Inc. to include iCell Neurons and iCell Endothelial Cells. The original distribution agreement, announced on June 8, 2011, covered the distribution of CDI's iCell Cardiomyocytes, the first commercially available product based on induced pluripotent stem cells (iPSCs), in Japan.

CDI is the world's largest manufacturer of human cellular tools for drug discovery and safety derived from iPSCs. The company currently manufactures iCell Cardiomyocytes, iCell Neurons and iCell Endothelial Cells with several other cell types, including liver cells, in development.

iPS Academia Japan was originally established to manage the patents and technology arising from the work of Shinya Yamanaka, MD, PhD of Kyoto University. CDI was the first foreign company granted a license to Yamanaka's iPSC patent portfolio by iPS Academia Japan, announced in May 2010.

"The reliability and consistent quality of CDI's cardiomyocytes have proven to be a valuable product offering to our academic and pharmaceutical customers," said Shosaku Murayama, President and CEO of iPS Academia Japan. "We're already seeing demand for additional human cell types manufactured by CDI by our Japanese customers."

Robert Palay, CEO and chairman of the board of CDI, noted, "We view the expansion of our distribution agreement with iPS Academia Japan as a vote of confidence in our ability to provide human iPSC-derived cells in the quantity, quality and purity required for scientists to realize the full potential of their experiments. We look forward to future growth of our relationship with iPS Academia Japan as we launch new human cell types and in vitro human disease models."

About Cellular Dynamics International Cellular Dynamics International, Inc. (CDI) is a leading developer of next-generation stem cell technologies for drug development, cell therapy, tissue engineering and organ regeneration. CDI harnesses its unique manufacturing technology to produce differentiated tissue cells from any individual's stem cell line in industrial quality, quantity and purity. CDI is accelerating the adoption of pluripotent stem cell technology, adapting its methods to fit into standard clinical practice by the creation of individual stem cell lines from a standard blood draw. CDI was founded in 2004 by Dr. James Thomson, a pioneer in human pluripotent stem cell research at the University of Wisconsin-Madison. CDI's facilities are located in Madison, Wisconsin. See http://www.cellulardynamics.com.

About iPS Academia Japan, Inc. iPS Academia Japan, Inc. (AJ) is an affiliate of Kyoto University, and its main role is, among other activities, to manage and utilize the patents and other intellectual properties held/controlled by Kyoto University and other universities in the field of iPSC technologies so that the research results contribute to health and welfare worldwide.

AJ was established in Kyoto in June 2008. AJ's patent portfolio consists of about 60 patent families (the total number of patent applications is about 220 cases) in the iPSC technology as of March 2012, and about 50 license arrangements have been executed with domestic or international enterprises. See http://ips-cell.net.

View post:
Cellular Dynamics Expands Distribution Agreement with iPS Academia Japan, Inc. to Include Distribution of iCell ...

Recommendation and review posted by sam

27-03-2012 13:19 G. Steven Burrill of Burrill & Company, reflects on current trends, challenges and the future of personalized medicine.

More here:
G. Steven Burrill on Personalized Medicine - Video

Recommendation and review posted by sam

March 27, 2012

According to a new study, using a patients own bone marrow may help repair damaged areas of the heart caused by heart failure.

Researchers found that left ventricular ejection fraction increased by 2.7 percent in patients who received stem cell therapy.

The study, which was presented at the American College of Cardiologys 61st Annual Scientific Session, revealed that the improvement in ejection fraction correlated with the number of CD34+ and CD133+ cells in the bone marrow.

This is the kind of information we need in order to move forward with the clinical use of stem cell therapy, Emerson Perin, MD, PhD, director of clinical research for cardiovascular medicine at the Texas Heart Institute and the studys lead investigator, said at the event.

The study included 92 patients who were randomly selected to receive stem cell treatment or placebo. The patients all had chronic ischemic heart disease and an ejection fraction of less than 45 percent along with heart failure.

Doctors placed a catheter in the hearts left ventricle to inject 3 ccs, or 100 million stem cells, into an average of 15 sites of the stem cell patients hearts.

The doctors used electromechanical mapping of the heart to measure the voltage in areas of the heart muscle and create a real-time image of the heart.

With this mapping procedure, we have a roadmap to the heart muscle, said Dr. Perin. Were very careful about where we inject the cells; electromechanical mapping allows us to target the cell injections to viable areas of the heart.

The trial was designed to determine whether left ventricular end systolic volume and myocardial oxygen consumption improved in patients who received stem cell treatment.

Continue reading here:
Cell Therapy Improves Damaged Heart In Study

Recommendation and review posted by simmons

The Worldwide Innovative Networking (WIN) Consortium in personalized cancer medicine proudly announces today that Foundation Medicine, Inc. (FMI), Cambridge, MA, joins WIN Consortium and becomes a member of the Consortium. The organizations' collaborative research strategy will be presented at the WIN2012 Symposium in Paris, France, on 28-29 June.

WIN Consortium, WIN2012, WIN Symposium, Worldwide Innovative Networking in cancer personalized medicine (Photo: Business Wire)

WIN Consortium, is a network of 22 academic institutions and industries across the globe, initiated by Cancer Institute Gustave Roussy (IGR), France and University of Texas MD Anderson Cancer Center, USA (MDACC), focusing on biomarker-driven therapeutic clinical trials conducted worldwide.

"The membership of Foundation Medicine, a CLIA certified laboratory using a next generation sequencing platform (NGS), is an opportunity for WIN to access their extensive screening test for aberrations in genes known to be associated with human cancer. WIN Consortium is sponsoring a unique clinical trial matching the genetics of patients' tumors and their responses to targeted therapies, to enable treatment with the therapies most likely to be effective against each individual patient's cancer. Foundation Medicine's participation will be a key strategic feature of WIN Consortium's innovative trial, conducted by Drs. Jean Charles Soria (IGR, France), Razelle Kurzrock (MDACC, USA), Josep Tabernero (VHIO, Spain) and Raanan Berger, (CSMC, Israel)," said Dr. John Mendelsohn, chairman of WIN Consortium.

"Foundation Medicine's industry and academic partnership through this international network complements the company's core cancer diagnostics capability, a fully informative genomic profile that provides physicians with clinically relevant molecular information designed to assist Oncologists in the selection of therapies for their patients and that to match patients with clinical trials specific for their tumor," said Michael J. Pellini, M.D., president and chief executive officer of Foundation Medicine. "The clinical trial to be announced during WIN2012, represents an important opportunity to use cutting edge NGS technology in an international setting for treatment decisions and we are proud to be supporting WIN Consortium with our platform."

"To hear more about the collaborative efforts of Foundation Medicine and WIN Consortium, join the WIN2012 Symposium in Paris on 28-29 June, a unique scientific event dedicated to the efficacy of personalized cancer therapeutics. Participants include outstanding investigators from academic institutions and industry - in an open exchange format. The WIN2012 scientific program received the endorsements of ASCO, ESMO, UICC and INCa (*). The WIN Symposium is a unique forum and networking opportunity. Plan your travel and register now as June is a busy period in Paris," said Vladimir Lazar, Chief operating officer of WIN Consortium.

Online abstract submission deadline is May 1st. Abstract will be published in a prestigious international journal, referenced on Pub Med. Early registration closed on April 1st.

About Foundation Medicine

Foundation Medicine is dedicated to improving cancer care through the development of comprehensive NGS cancer diagnostics that identify and interpret an ever-growing set of actionable genomic alterations. Founding advisors are world leaders in genome technology, cancer biology and medical oncology. Please visit the company's website at http://www.foundationmedicine.com.

Disclaimers:

Read this article:
Foundation Medicine, Cambridge, MA, Joins WIN Consortium (Paris) and Becomes Member of the Worldwide Innovative ...

Recommendation and review posted by sam

Posted: Tuesday, March 27, 2012 4:00 am | Updated: 7:09 am, Tue Mar 27, 2012.

The former Pine Tree ISD administration building is filled with vendors selling their wares lots of bling, cosmetics, sunglasses, watches, pashmina ponchos, scarves, purses, cookware, kitchen items, T-shirts and more. The vendors, all women, giggle as they talk to each other and customers alike.

A stranger wouldnt know its a fundraiser for Pine Tree High School sophomore Christopher Sartor, who suffered a spinal cord injury in September while lifting weights at school under the supervision of the high school coaching staff.

No, I dont know him, Sassy Lady Designs vendor Evelyn Hughes said. But Chris is one of ours. And in Pine Tree, we take care of our own.

We still consider ourselves a small community.

Terry Barrett, teacher and sponsor of the Pine Tree Leadership Class, said the students are always involved in community activities, so doing a fundraiser for the student wasnt ever a question.

At Pine Tree, we take care of our own, she said, echoing the phrase that came up repeatedly. This has been a tremendous change of lifestyle for Chris ... and for his family. With this change has come many out of pocket expenses for his family. We are trying to help alleviate part of the burden.

Barrett said the class brainstormed about possible fundraising activities.

There are so many car washes and dinners, she said. The class settled on holding a bazaar and charging per booth. The exception is Masquerade, which is donating a percentage of its proceeds.

During the event Monday, a teenage girl picked up earrings, exclaiming, Oh, mom, can I have these?

Here is the original post:
Pine Tree comes to the aid of student with spinal cord injury

Recommendation and review posted by sam